Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer
Clinical Journal of Oncology Nursing · 01.06.2020 · 24 (3) · 277-283
DOI: 10.1188/20.cjon.277-283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of Oncology Nursing, online erschienen am 01.06.2020. Verfasst von Marianne Davies und 1 weiteren Autor:innen. Beteiligte Einrichtung: Yale Comprehensive Cancer Center. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yale Comprehensive Cancer Center.
- Smilow Cancer Hospital at Yale-New Haven Hospital.
ORCID-Profile: Marianne Davies
Zitieren
APA
Davies, M., & Duffield, E. (2020). Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer. Clinical Journal of Oncology Nursing, 24(3), 277-283. https://doi.org/10.1188/20.cjon.277-283
Vancouver
Davies M, Duffield E. Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer. Clinical Journal of Oncology Nursing. 2020;24(3):277-283. doi:10.1188/20.cjon.277-283
BibTeX
@article{Davies2020,
author = {Davies, Marianne and Duffield, Emily},
title = {Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer},
journal = {Clinical Journal of Oncology Nursing},
year = {2020},
volume = {24},
number = {3},
pages = {277--283},
doi = {10.1188/20.cjon.277-283}
}
EUVIMED